Heme Oxygenase 1‐Targeted Hybrid Nanoparticle for Chemo‐ and Immuno‐Combination Therapy in Acute Myelogenous Leukemia
- Title
- Heme Oxygenase 1‐Targeted Hybrid Nanoparticle for Chemo‐ and Immuno‐Combination Therapy in Acute Myelogenous Leukemia
- Author
- 김용희
- Keywords
- acute myelogenous leukemia; cancer immunotherapy; heme oxyge-nase 1-targeted leukemia immunotherapy; heme oxygenase 1-targeted nanomedicine; immunotherapeutic nanomedicine
- Issue Date
- 2020-06
- Publisher
- WILEY
- Citation
- ADVANCED SCIENCE, v. 7, no. 13, article no. 2000487
- Abstract
- Acute myelogenous leukemia (AML) is a fatal blood cancer with high patient mortality. Daunorubicin and cytarabine are first-line chemotherapy for AML, with bone marrow transplantation in most cases. Recently, cancer immunotherapy has been challenged in AML and leukemia-niche myeloid cells are promising targets for the AML immunotherapy. Heme oxygenase 1 (HO1) is an antioxidative and cytoprotective enzyme inducing chemo-resistant AML and has been focused as an immune checkpoint molecule in tumor microenvironments. Herein, lipid-polymer hybrid nanoparticle (hNP) is loaded with tin mesoporphyrin (SnMP), a HO1-inhibitor, and non-covalently modified with an engineered antibody for leukemic cell-targeted delivery. HO1-inhibiting T-hNP (T-hNP/SnMP) enhances chemo-sensitivity in human leukemia cells. In a human AML-bearing orthotopic mouse model, intravenously injected T-hNP not only actively targets to human leukemia cells but passively targets to CD11b+ myeloid cells in a bone marrow niche. The T-hNP/SnMP enhances the chemo-therapeutic effect of daunorubicin and boosts immune response by reprogramming bone marrow myeloid cells resulting from the recruitment of the monocyte-lineage and induction of inflammatory genes. The ex vivo study demonstrates an enhanced immune response of HO1-inhibited bone marrow CD11b+ myeloid cells against apoptotic leukemia cells. Collectively, HO1-inhibiting dual cell-targeted T-hNP/SnMP has a strong potential as a novel therapeutic in AML.
- URI
- https://onlinelibrary.wiley.com/doi/10.1002/advs.202000487https://repository.hanyang.ac.kr/handle/20.500.11754/168855
- ISSN
- 2198-3844
- DOI
- 10.1002/advs.202000487
- Appears in Collections:
- COLLEGE OF ENGINEERING[S](공과대학) > BIOENGINEERING(생명공학과) > Articles
- Files in This Item:
- Heme Oxygenase 1-Targeted Hybrid Nanoparticle for Chemo- and Immuno-Combination Therapy in Acute Myelogenous Leukemia.pdfDownload
- Export
- RIS (EndNote)
- XLS (Excel)
- XML